Domača stranCVM • NYSEAMERICAN
add
CEL-SCI Corp
0,73 $
Po zaprtju:(1,80 %)−0,013
0,71 $
Konec trgovanja: 8. nov., 16:09:36 GMT -5 · USD · NYSEAMERICAN · Izjava
Prejšnji trg. dan.
0,70 $
Dnevni razpon
0,70 $ - 0,75 $
Letni razpon
0,68 $ - 3,23 $
Tržna kapitalizacija
44,75 mio. USD
Povprečni obseg
300,10 tis.
Razm. P/E
-
Dividendna donosnost
-
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 1,97 mio. | −19,84 % |
Čisti dohodek | −7,52 mio. | 10,17 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | — | — |
EBITDA | −5,69 mio. | 20,98 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 435,78 tis. | −91,55 % |
Skupna sredstva | 24,07 mio. | −25,53 % |
Skupne obveznosti | 15,60 mio. | −11,03 % |
Celoten lastniški kapital | 8,47 mio. | — |
Shares outstanding | 61,49 mio. | — |
Razmerje P/B | 4,37 | — |
Donosnost sredstev | −61,63 % | — |
Donosnost kapitala | −70,15 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −7,52 mio. | 10,17 % |
Denar iz dejavnosti | −4,58 mio. | 19,19 % |
Denar iz naložb | −23,47 tis. | 88,08 % |
Denar iz financiranja | −322,30 tis. | −133,87 % |
Neto sprememba denarnih sredstev | −4,92 mio. | −0,27 % |
Prost denarni tok | −1,94 mio. | 32,46 % |
Vizitka
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
Datum ustanovitve
mar. 1983
Sedež organizacije
Spletno mesto
Zaposleni
43
